CA2678258A1 - Treprostinil treatment for interstitial lung disease and asthma - Google Patents

Treprostinil treatment for interstitial lung disease and asthma Download PDF

Info

Publication number
CA2678258A1
CA2678258A1 CA002678258A CA2678258A CA2678258A1 CA 2678258 A1 CA2678258 A1 CA 2678258A1 CA 002678258 A CA002678258 A CA 002678258A CA 2678258 A CA2678258 A CA 2678258A CA 2678258 A1 CA2678258 A1 CA 2678258A1
Authority
CA
Canada
Prior art keywords
treprostinil
pulmonary fibrosis
pharmaceutically acceptable
kit
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002678258A
Other languages
English (en)
French (fr)
Inventor
Michael Wade
Stuart Rich
Eugene Sullivan
Robert Roscigno
Roger Jeffs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Therapeutics Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2678258A1 publication Critical patent/CA2678258A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
CA002678258A 2007-02-09 2008-02-08 Treprostinil treatment for interstitial lung disease and asthma Abandoned CA2678258A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90032007P 2007-02-09 2007-02-09
US60/900,320 2007-02-09
US94021807P 2007-05-25 2007-05-25
US60/940,218 2007-05-25
PCT/US2008/053467 WO2008098196A1 (en) 2007-02-09 2008-02-08 Treprostinil treatment for interstitial lung disease and asthma

Publications (1)

Publication Number Publication Date
CA2678258A1 true CA2678258A1 (en) 2008-08-14

Family

ID=39357950

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002678258A Abandoned CA2678258A1 (en) 2007-02-09 2008-02-08 Treprostinil treatment for interstitial lung disease and asthma

Country Status (7)

Country Link
US (4) US20080280986A1 (enExample)
EP (2) EP2120961A1 (enExample)
JP (2) JP2010518122A (enExample)
KR (1) KR20090117781A (enExample)
CN (2) CN101678033A (enExample)
CA (1) CA2678258A1 (enExample)
WO (1) WO2008098196A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2622471T5 (es) * 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
CN101287457B (zh) * 2004-04-12 2011-11-16 联合治疗公司 Treprostinil用于治疗神经性糖尿病的足部溃疡的用途
US20070023047A1 (en) * 2005-07-26 2007-02-01 Moshe Zalsman Face mask particularly useful as medical face mask
EP1962805B1 (en) 2005-12-08 2016-07-06 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
JP5797376B2 (ja) 2006-05-15 2015-10-21 ユナイテッド セラピューティクス コーポレーション 定量吸入器を用いたトレプロスチニル投与
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
EP3287434A1 (en) 2007-12-17 2018-02-28 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in remodulin ®
CA2723540C (en) * 2008-05-08 2016-01-05 United Therapeutics Corporation Treprostinil monohydrate
KR101544246B1 (ko) * 2009-05-07 2015-08-12 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린 유사체의 고체 제제
ES2451790T3 (es) * 2009-08-07 2014-03-28 Scipharm Sàrl Composición para el tratamiento de la fibrosis quística
JP5681276B2 (ja) 2010-03-15 2015-03-04 ユナイテッド セラピューティクス コーポレイション 肺高血圧症のための治療
CA3029711A1 (en) 2010-06-03 2011-12-08 United Therapeutics Corporation Treprostinil production
US20120010159A1 (en) * 2010-07-09 2012-01-12 United Therapeutics Corporation Combination therapies with cox-2 inhibitors and treprostinil
WO2012107364A1 (en) * 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
BR112013019335B1 (pt) * 2011-02-07 2022-05-31 Scipharm Sàrl Nova composição, método para aumentar o nível de camp em um célula e combinação terapêutica, para o tratamento da fibrose cística
WO2012118943A1 (en) 2011-03-02 2012-09-07 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
HK1198358A1 (en) * 2011-08-12 2015-04-10 Ascendis Pharma A/S Sustained release composition of prostacyclin
HK1198359A1 (en) 2011-08-12 2015-04-10 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
CN103193627B (zh) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193626B (zh) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
US20150272874A1 (en) * 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP4137127A1 (en) 2013-01-11 2023-02-22 Corsair Pharma, Inc. Prodrugs of treprostinil
CA3212313A1 (en) 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
WO2014150203A1 (en) 2013-03-15 2014-09-25 United Therapeutics Corporation Salts of treprostinil
CA2908244C (en) 2013-03-25 2021-04-20 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
KR102296259B1 (ko) 2013-10-25 2021-08-30 인스메드 인코포레이티드 프로스타사이클린 화합물, 조성물 및 이의 사용 방법
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
PT3142643T (pt) 2014-05-15 2019-10-28 Insmed Inc Métodos para o tratamento de infeções mico bacterianas pulmonares não tuberculares
US20170088897A1 (en) * 2014-06-03 2017-03-30 Novartis Ag Pulmonary hypertension biomarker
WO2015192030A1 (en) 2014-06-13 2015-12-17 United Therapeutics Corporation Treprostinil formulations
CA2964804C (en) 2014-10-20 2019-04-02 United Therapeutics Corporation Synthesis of intermediate for producing prostacyclin derivatives
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US10632129B2 (en) 2014-12-03 2020-04-28 Steadymed Ltd. Preservative-free treprostinil formulations and methods and devices for use with same
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
EP3515430A1 (en) 2016-09-26 2019-07-31 United Therapeutics Corporation Treprostinil prodrugs
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
CN108379557A (zh) * 2018-01-15 2018-08-10 吉林大学 使用白介素因子-37治疗特发性肺纤维化
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS
ES2976468T3 (es) 2018-09-18 2024-08-01 Lilly Co Eli Sal de treprostinil erbumina
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
EP4017588A1 (en) 2019-08-23 2022-06-29 United Therapeutics Corporation Treprostinil prodrugs
JP2023523557A (ja) * 2020-04-17 2023-06-06 ユナイテッド セラピューティクス コーポレイション 間質性肺疾患の治療における使用のためのトレプロスチニル
CN116113415A (zh) 2020-06-09 2023-05-12 联合治疗公司 曲前列尼尔的富马酰基二酮哌啶前药
AU2021401921A1 (en) 2020-12-14 2023-07-06 United Therapeutics Corporation Methods of treating disease with treprostinil prodrugs
AU2022229367A1 (en) 2021-03-03 2023-09-14 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
PT90888B (pt) * 1988-06-17 1994-12-30 Wellcome Found Processo para a preparacao de composicoes farmaceuticas contendo prostaglandinas
GB8814438D0 (en) * 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
US6441245B1 (en) * 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
CA2312729C (en) * 1997-11-14 2006-05-23 United Therapeutics Corporation Use of 9-deoxy-2', 9-.alpha.-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
WO2000055314A2 (en) * 1999-03-18 2000-09-21 United Therapeutics Corporation Inhibitors of endothelin-1 synthesis
US6756047B2 (en) * 2000-05-12 2004-06-29 The University Of Toledo Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
ES2622471T5 (es) * 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
JP5797376B2 (ja) * 2006-05-15 2015-10-21 ユナイテッド セラピューティクス コーポレーション 定量吸入器を用いたトレプロスチニル投与

Also Published As

Publication number Publication date
EP2491932A2 (en) 2012-08-29
CN101678033A (zh) 2010-03-24
WO2008098196A1 (en) 2008-08-14
JP2010518122A (ja) 2010-05-27
US20080280986A1 (en) 2008-11-13
EP2120961A1 (en) 2009-11-25
KR20090117781A (ko) 2009-11-12
CN102648916A (zh) 2012-08-29
EP2491932A3 (en) 2012-12-12
US20130096200A1 (en) 2013-04-18
US20120129941A1 (en) 2012-05-24
US20140018431A1 (en) 2014-01-16
JP2013189459A (ja) 2013-09-26

Similar Documents

Publication Publication Date Title
US20130096200A1 (en) Treprostinil treatment for interstitial lung disease and asthma
ES2331187T3 (es) Utilizacion de treprostinil para mejorar las funciones renales.
Choi et al. Serum irisin levels in new-onset type 2 diabetes
US4762820A (en) Therapeutic treatment for congestive heart failure
Delclaux et al. Factors associated with dyspnea in adult patients with sickle cell disease
US20140322226A1 (en) Acth for treatment of acute respiratory distress syndrome
Chon et al. Effects of long-term iloprost treatment on right ventricular function in patients with Eisenmenger syndrome
CN115867575A (zh) 用il-33轴结合拮抗剂治疗急性呼吸窘迫综合征
Yang et al. Interleukin-9 aggravates isoproterenol-induced heart failure by activating signal transducer and activator of transcription 3 signalling
CN106413740A (zh) 用于降低gdf‑15的serelaxin应用
US20130115640A1 (en) ACTH for Treatment of Kidney Disease
CA2622016A1 (en) Interferon lambda therapy for treatment of respiratory diseases
Gao et al. Diterpenoid DGT alleviates atopic dermatitis–like responses in vitro and in vivo via targeting IL-4Rα
JP2025502098A (ja) うつ病の治療のための組成物及び方法
JP2020518604A (ja) Ｉｌ−１７アンタゴニストを使用して喘息を選択的に治療する方法
US20250387391A1 (en) A soluble guanylat cyclase activator for treating chronic vascular dysfunction
US20170082643A1 (en) A novel soluble biomarker for insulin resistance
Karsentya et al. SESSION PL ENIERE: METABOLISMES, DU GENE AU PATIENT
Ott et al. Symptoms of premenstrual syndrome may be caused by hyperventilation
Leggate The IL-6 system and its interaction with chronic low-grade inflammation and high intensity intermittent exercise
WO2025037259A1 (en) Methods and compositions for preventing or treating severe asthma
Mandel et al. Prospective studies of thyroid function in patients receiving gold therapy
TW201601741A (zh) 用於治療ｅｓｒｄ病患之ｐｅｗ的肌肉生長抑制素拮抗劑
De Ciuceis et al. CIRCULATING INDICES OF INFLAMMATION/OXIDATIVE STRESS IN NORMOTENSIVE AND HYPERTENSIVE OBESE PATIENTS: PP. 26.339
Acharya Evaluation of Systemic Cytokines IL-1β, IL-4, IL-6, IL-10 and TNF-α in Health, Chronic Periodontitis and Type 2 Diabetes Mellitus

Legal Events

Date Code Title Description
EEER Examination request
EEER Examination request

Effective date: 20121206

FZDE Discontinued

Effective date: 20161011